April 2016, Vol. 5, No. 3
Improving Value by Understanding Total Cost of Cancer Care
2016 ASCO Quality Care Symposium
Aggressive cancer treatments, emergency department (ED) visits, and hospital admissions at the end of life are major cost drivers. The use of cost data to inform infrastructure investments can help cancer centers to move toward value-based payment models, improve end-of-life planning, and reduce futile care, according to Kerin Adelson, MD.
The more procedures performed, drugs prescribed, and hospitalizations made, â€śthe more money feeds into your institution,â€ť said Adelson, Assistant Professor of Medicine (Medical Oncology) and Chief Quality Officer and Deputy Chief Medical Officer for Smilow Cancer Hospital (SCH) at Yale-New Haven. â€śItâ€™s aspirational to think the best, highest quality care would be remunerated accordingly, but for most institutions, this change still seems far off.â€ť
â€śIn healthcare, higher cost does not mean higher quality,â€ť she continued. â€śOften in the setting of advanced disease, costly drugs, invasive procedures, and repeated hospitalizations do not improve outcomes.â€ť
According to Adelson, cancer centers across the country are largely unprepared to move toward value-based payment, but her institution is tackling this challenge by analyzing cost data. She presented her groupâ€™s findings at the 2016 ASCO Quality Care Symposium.
Preparing for Value
â€śStep 1 of preparing for value is demonstrating that this is an opportunity, not a liability,â€ť she stated. The inspiration for the value-based strategy at SCH was the Oncology Care Model (OCM) from the Centers for Medicare & Medicaid Services.
â€śOCM is a win-win,â€ť she said. â€śWe learn how to improve value without giving up fee-for-service, and we receive financial support to invest in infrastructure that will improve care.â€ť
Medicare patients are enrolled at the time chemotherapy is initiated, in 6-month episodes, and fee-for-service is collected for all care delivery. The practice collects an additional $160 per patient per month to support new infrastructure and care processes. Performance-based payments are structured on the shared savings model, and quality metrics are met.
The 8 metrics associated with performance-based payments include such items as number of ED visits per patient/episode and number of hospital admissions per patient/episode, which she deemed â€śtruly meaningful quality metrics…that could catalyze clinical transformation.â€ť
The second step in preparing for value is knowing your strengths and building upon them, but also understanding your weaknesses.
The third step is understanding your populationâ€™s total cost of care. â€śThis requires payer level data and cannot be obtained with your own institutionâ€™s financial reports. Understanding when in the trajectory of illness spending occurs and what care patterns lead to higher cost will identify opportunities for savings,â€ť she said.
The researchers accessed the 5% Medicare Limited Data Set (2012-2013) to map out the cost of care in 6-month episodes for all Medicare patients receiving chemotherapy at SCH. â€śIndeed, we saw that 20% of cost is incurred outside of our health system,â€ť said Adelson.
On average, a first episode of care at SCH cost $26,500, a second episode $38,000, and a third $45,600. Their analysis also demonstrated important associations between increases in spending and ED utilization. Patients who had 1 or fewer ED visits during an episode averaged $21,000 versus $49,000 for those with 2 or more. â€śThis cost is driven by the downstream inpatient services,â€ť she said. And patients who died during an episode cost $53,000 compared with $25,600 for patients who lived.
The Importance of Urgent Care
The investigators used their analysis to target infrastructure investments in urgent care, care management, and palliative care.
â€śThe Medicare database showed us that our elderly population has substantial comorbidity, suggesting the need for better care management,â€ť said Adelson. â€śWe looked at causes of admissions outside the primary cancer diagnosis. Many of these could be prevented with enhanced ambulatory urgent care and extended early morning and evening hours.â€ť
â€śReferrals to ambulatory palliative care earlier in the course of the disease will help patients express their wishes and goals, and for patients with disease progression, our goal is to initiate referrals to hospice from the ambulatory setting,â€ť Adelson added. â€śThis is a big change from our care today.â€ť
The final step in preparing for value is planning for infrastructure investments that will align quality improvement and cost savings. â€śChanging how we care for patients at the end of life requires a major cultural shift, which is challenging for oncologists,â€ť she said. â€śWe will provide communication training for all of our oncologists and hematologists to help them elicit patient preferences earlier in the course of disease, and finally, we will implement clinical pathways to standardized evidence-based cost-effective care across our large network.â€ť
â€śWe believe these investments will lead to significant cost reductions,â€ť she said.
NCI-MATCH: A Paradigm Shift in the Evolution of Personalized Medicine Trials
An Interview with Douglas R. Lowy, MD, of the National Cancer Institute
Precision medicine has become a high-profile term with equally as high expectations. With the presidentâ€™s announcement last year of a Precision Medicine Initiative (PMI) and his more recent calling for a â€śmoonshotâ€ť to cure cancer headed by Vice President Biden, the march toward personalizing care continues to gain momentum. In [ Read More ]
Making Strides in Personalizing Medicine
Dear Colleague, This generation has witnessed amazing advances in the realm of precision medicine. It has learned that making personalized medicine a reality takes forward movement on many frontsâ€”from basic research to novel drugs, from clinical trials to policy. Within our pages, we strive to present the full range of [ Read More ]